Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study
Authors:
- Iain B McInnesIMIain B McInnes
- Philip J MeasePMPhilip J Mease
- Alan J KivitzAKAlan J Kivitz
- Peter NashPNPeter Nash
- Proton RahmanPRProton Rahman
- Jürgen RechJRJürgen Rech
- Philip G ConaghanPCPhilip G Conaghan
- Bruce KirkhamBKBruce Kirkham
- Sandra NavarraSNSandra Navarra
- Ashwini D BelsareABAshwini D Belsare
- Eumoprhia M DelichaEDEumoprhia M Delicha
- Luminita PricopLPLuminita Pricop
- 1 April 2020
- journal article
- Published by Elsevier in The Lancet Rheumatology
- Vol. 2 (4) , e227-e235
Abstract
No abstract availableKeywords
Funding Information
- Novartis Pharma
- National Institute for Health and Care Research
This publication has 30 references indexed in Scilit:
- Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatologyAnnals of the Rheumatic Diseases, 2015
- Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisAnnals of the Rheumatic Diseases, 2015
- Adverse effects of TNF inhibitors in SpA: Are they different from RA?Best Practice & Research Clinical Rheumatology, 2014
- Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)Annals of the Rheumatic Diseases, 2014
- The Th17 axis in psoriatic disease: pathogenetic and therapeutic implicationsAutoimmunity Highlights, 2014
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Burden of Disease: Psoriasis and Psoriatic ArthritisAmerican Journal of Clinical Dermatology, 2013
- Early Psoriatic ArthritisRheumatic Disease Clinics of North America, 2012
- Hepatitis B virus reactivation during therapy with etanercept in an HBsAg‐negative and anti‐HBs‐positive patientLiver International, 2008
- Prevalence of Joint Disease in Patients with PsoriasisAmerican Journal of Clinical Dermatology, 2003